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An efﬁcient shim system and an optimized localization se-
quence were used to measure in vivo 1H NMR spectra from
cerebral cortex, hippocampus, striatum, and cerebellum of
C57BL/6 mice at 9.4 T. The combination of automatic ﬁrst- and
second-order shimming (FASTMAP) with strong custom-de-
signed second-order shim coils (shim strength up to 0.04 mT/
cm2) was crucial to achieve high spectral resolution (water line
width of 11–14 Hz). Requirements for second-order shim
strengths to compensate ﬁeld inhomogeneities in the mouse
brain at 9.4 T were assessed. The achieved spectral quality
(resolution, S/N, water suppression, localization performance)
allowed reliable quantiﬁcation of 16 brain metabolites (LCModel
analysis) from 5–10-L brain volumes. Signiﬁcant regional dif-
ferences (up to 2-fold, P < 0.05) were found for all quantiﬁed
metabolites but Asp, Glc, and Gln. In contrast, 1H NMR spectra
measured from the striatum of C57BL/6, CBA, and CBA/BL6
mice revealed only small (<13%, P < 0.05) interstrain differ-
ences in Gln, Glu, Ins, Lac, NAAG, and PE. It is concluded that
1H NMR spectroscopy at 9.4 T can provide precise biochemical
information from distinct regions of the mouse brain noninva-
sively that can be used for monitoring of disease progression
and treatment as well as phenotyping in transgenic mice
models. Magn Reson Med 52:478–484, 2004. © 2004 Wiley-
Liss, Inc.
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The development of transgenic mouse models for human
brain diseases represented a major advance in the investi-
gation of the pathogenesis of several brain disorders (1–4).
Because of the cost and effort involved in developing such
transgenic mouse models, noninvasive methods are desir-
able that allow a longitudinal study design to characterize
the expressed phenotype and to monitor the progress of
neurodegeneration or drug treatment. In vivo NMR spec-
troscopy is a unique experimental technique that allows
noninvasive quantiﬁcation of brain metabolites. In vivo 1H
NMR spectroscopy has been widely used to study the
brain of rats and more than 100 articles have been pub-
lished (e.g., see reviews 5, 6). However, a relatively small
number of studies have focused on the mouse brain (7–15).
This was partly caused by the small size of the mouse
brain resulting in limited signal/noise ratio (S/N). In addi-
tion, signals were broad due to the difﬁculties to compen-
sate local magnetic ﬁeld inhomogeneity in the small
mouse head (7–13). Poor spectral resolution strongly lim-
ited the number of quantiﬁed metabolites and most of the
in vivo 1H NMR studies of the mouse brain to date have
only reported signal intensity ratios of N-acetylaspartate,
creatine, and choline (7,9,11–13,16).
Recently, it has been shown that automatic adjustment
of ﬁrst- and second-order shims (17,18) combined with
efﬁcient localization methods (19) can provide highly re-
solved in vivo 1H NMR spectra at 9.4 T. The excellent
spectral resolution, accurate localization, and high sensi-
tivity resulted in the reliable quantiﬁcation of more than
15 metabolites (termed “neurochemical proﬁle”) in the rat
brain (20,21). Studies of brain development showed
(22,23) that high-quality spectra could also be obtained
from the small head of rat pups provided that the second-
order shim system was strong enough to compensate non-
linear ﬁeld inhomogeneities in the selected volume of
interest (VOI).
As a result of the increased demands on second-order
shim strength, our 9.4 T magnet was upgraded in 2001
with very strong second-order shim coils. The ﬁrst aim of
the present study was to demonstrate that highly spec-
trally and spatially resolved in vivo 1H NMR spectra of the
mouse brain at 9.4 T can be obtained using such shimming
capabilities. A secondary aim was to determine the extent
and reliability of neurochemical information that can be
extracted from those spectra.
MATERIALS AND METHODS
Animals
All experiments were performed according to procedures
approved by the Institutional Animal Care and Use Com-
mittee. Spontaneously breathing mice (20–25 g) were
placed in a plastic chamber and anesthetized by the su-
perﬂuous ﬂow of a gas mixture containing N2O and O2 in
a 1:1 ratio with 1.2–1.5% of isoﬂurane. The air tempera-
ture surrounding the mouse chamber was maintained at
30°C by warm water circulation and veriﬁed by a thermo-
sensor. The duration of a study for a single mouse did not
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exceed 2 hr. The C57BL/6 mouse strain (n 9) was used to
study regional changes in concentrations of brain metabo-
lites. In vivo 1H NMR spectra from the cerebral cortex,
hippocampus, striatum, and cerebellum were measured in
7, 8, 6, and 6 of these 9 mice, respectively. Two additional
mouse strains (CBA, n  5, and CBA/BL6, n  9) were
used to investigate the effect of the strain type on metab-
olite concentrations in a speciﬁc brain region.
1H NMR Spectroscopy
All experiments were performed on a 9.4 T/31cm magnet
(Magnex Scientiﬁc, Abingdon, UK) equipped with an
11 cm gradient coil (300 mT/m, 500 s) and strong custom-
designed second-order shim coils (Magnex Scientiﬁc) with
maximum strengths of XZ  3.8  10-2 mT/cm2, YZ 
4.5  10-2 mT/cm2, Z2  3.2  10-2 mT/cm2, XY  1.2 
10-2 mT/cm2, X2Y2  1.3  10-2 mT/cm2 at a current of
4 A. The magnet was interfaced to a Varian INOVA console
(Varian, Palo Alto, CA). A quadrature transmit/receive sur-
face RF coil with two geometrically decoupled single-turn
coils (14 mm diameter) was used (24). All ﬁrst- and sec-
ond-order shim terms were automatically adjusted for
each VOI using FASTMAP with EPI readout (17,18). The
water signal was efﬁciently suppressed by variable power
RF pulses with optimized relaxation delays (VAPOR) (19).
Outer volume suppression (OVS) combined with the ultra-
short echo-time STEAM (TE  2 ms, TM  20 ms, TR 
5 sec, spectral width  5000 Hz, number of acquired
complex points 2048) was used for localization (19). The
amplitudes of the crusher gradients in the STEAM se-
quence were increased (relative to the original version that
was developed for an adult rat brain) to avoid the rephas-
ing of unwanted magnetization during acquisition due to
the highly inhomogeneous B0 ﬁeld outside the VOI. The
chemical shift displacement error was minimized by using
broadband RF pulses (13.5 kHz in STEAM, 35 kHz in OVS)
combined with ﬁeld gradients of 100–200 mT/m for slice
selection. The data sampling started before the maximum
of a stimulated echo (STE) to eliminate baseline distor-
tions resulting from the incorrect amplitude of the ﬁrst few
data points after turning on the receiver. Those data points
before STE were discarded in postprocessing. In addition,
the timing of the ﬁrst data point of the STE was carefully
adjusted to eliminate the need for any ﬁrst-order phase
correction.
Driving the second-order shim coils to the maximum of
their capacity resulted in a B0 ﬁeld drift up to 10 Hz/min.
Similar ﬁeld drifts due to insufﬁcient heat extraction from
the shim coils have been reported (25). Because real-time
frequency corrections were not available on the Varian
console, the drift of the resonance frequency was mea-
sured just before the data collection and then all frequen-
cies in the pulse sequence were changed from scan to scan
to follow the ﬁeld drift and to remain close to an on-
resonance condition. In addition, each individual FID was
stored separately on disk, while maintaining the complete
phase cycle. After data collection, FIDs were added in
blocks of 4 or 8 (depending on S/N) and the residual
frequency drift was eliminated using the signal of the
methyl group of creatine. Then all blocks were summed
and small residual eddy current effects were corrected
using a reference water signal collected for each location.
The position of the VOI was based on multislice RARE
images (echo train length ETL  8, echo spacing 15 ms,
TE  60 ms, number of phase encoding steps  256,
FOV  20  20 mm, slice thickness  1 mm, number of
transients NT  2, TR  4 sec). 1H NMR spectra were
acquired from VOIs centered in the hippocampus, stria-
tum, cerebral cortex, and cerebellum. The size of the VOI
(5–10 L) was adjusted to ﬁt the anatomical structure of
the selected brain region and to minimize partial volume
effects.
Quantiﬁcation
In vivo 1H NMR spectra were analyzed using LCModel
(26,27) as in our previous studies, which focused on the rat
brain (20–23,28). The unsuppressed water signal mea-
sured from the same VOI was used as an internal reference
for the quantiﬁcation (assuming 80% brain water content).
The LCModel analysis calculates the best ﬁt to the exper-
imental spectrum as a linear combination of model spectra
(solution spectra of brain metabolites). The ﬁnal analysis is
performed in the frequency domain; however, raw data
(FIDs) are used as standard data input. The following 18
metabolites were included in the basis set: alanine (Ala),
aspartate (Asp), creatine (Cr), -aminobutyric acid
(GABA), glucose (Glc), glutamate (Glu), glutamine (Gln),
glutathione (GSH), glycerophosphorylcholine (GPC) phos-
phorylcholine (PCho), myo-inositol (Ins), lactate (Lac), N-
acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG),
phosphocreatine (PCr), phosphorylehtanolamine (PE),
scyllo-inositol, and taurine (Tau). In addition, the spec-
trum of macromolecules, experimentally measured in
the mouse brain with an inversion recovery experiment
using a short repetition time (TR  2.0 sec, TI  0.675
sec), was included in the basis set as previously de-
scribed (20–23,28).
Statistical analysis
The SPSS software package (SPSS, Chicago, IL) was used
for statistical analysis. The data for each metabolite were
tested for homogeneity of variances and one-way ANOVA
was used to compare the means.
RESULTS
The multislice RARE sequence provided high-quality im-
ages of the mouse brain with a spatial resolution and
contrast that guaranteed precise and reproducible place-
ment of the VOI in the hippocampus, striatum, cerebral
cortex, or cerebellum (Fig. 1). In vivo 1H NMR spectra from
corresponding brain regions shown in Fig. 1 represent the
spectral quality that was consistently achieved in this
study. In addition to the commonly observed NMR signals
of the methyl resonances of NAA, Cr, and Cho, character-
istic spectral patterns of other metabolites, such as Ala,
Asp, Glu, Gln, Ins, and Tau were discernible in 1H NMR
spectra from all four brain regions studied (Fig. 1). This
high spectral resolution was accomplished by using FAST-
MAP automated shimming supported by an efﬁcient shim
system. Speciﬁcally, the availability of a very strong cus-
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tom-design second-order shim coil was critical. Shimming
routinely resulted in unsuppressed water signal line
widths (FWHM) of 11–14 Hz.
A comparison of the average shim settings required to
compensate ﬁeld inhomogeneities in a particular brain
region clearly demonstrated that the demands for the sec-
ond-order shim strength were substantially higher in the
mouse brain relative to neonatal or adult rat brain (Fig. 2a).
The YZ and Z2 shims were the most important in the
hippocampus. With the exception of the Z2 shim, where
10 out of 15 experiments requested a shim value that
exceeded the maximum shim strength (shaded area), all
shims were within the available shim range. In addition, a
comparison of the shim requirements for different brain
regions in a single mouse strain (C57BL/6) emphasized
substantial spatial variation in local shims, with the high-
est demands on the XZ, YZ, and Z2 shims coils (Fig. 2b).
The custom-designed second-order shim coil was thus
strong enough to compensate most of the ﬁeld inhomoge-
neities in these studied regions of the mouse brain. Only
the requirements for the Z2 shim exceeded the available
maximum multiple times. The averaged shim require-
ments to compensate the ﬁeld inhomogeneities in striatum
were independent of the mouse strain (data not shown).
In vivo 1H NMR spectra were analyzed using LCModel
and the concentrations of 16 metabolites were reliably
quantiﬁed in cerebral cortex, hippocampus, striatum, and
cerebellum of C57BL/6 mice (Fig. 3). Because of the strong
cross-correlation between GPC and PCho arising from the
close spectral similarity, only the sum of GPC and PCho
was reported. The Cramer-Rao lower bounds (CRLB) cor-
responding to the ﬁtted metabolites are shown in Fig. 3a,b.
NAA, Glu and total creatine (Cr  PCr) were quantiﬁed
with CRLB  5% from all 27 processed spectra. Another
eight metabolites (Cr, PCr, GABA, Gln, Ins, Lac, Tau,
GPC  PCho) were quantiﬁed with CRLB  15% in all
brain regions (Fig. 3a). Glucose and GSH were quantiﬁed
with CRLB  25% and Ala, Asp, NAAG, and PE were
quantiﬁed with CRLB ranging between 15–35%. Ala and
Asp were not detected in cerebellum, Ala was also not
detected in striatum, and scyllo-inositol was not detected
in all brain regions (CRLB  50%). When expressing the
CRLB in mol/g (Fig. 3b) the estimated concentration er-
rors were between 0.2 and 0.4 mol/g for most of the
metabolites, independent of brain region and metabolite
concentration (VOI  5–10 L, NT  160–320). Signiﬁ-
cant differences between the brain regions were found for
nearly all brain metabolites (Fig. 3c). Metabolites such as
Cr, Glu, Ins, Lac, NAA, PE, Tau, and GPC  PCho showed
the largest regional variation in concentration (up to
2-fold) reaching the highest level of signiﬁcance (P 
0.0001).
In addition to the data from C57BL/6 mice, in vivo 1H
NMR spectra from the striatum of CBA and CBA/BL6 mice
were measured to investigate potential effects of strain
type on concentrations of brain metabolites. The striatal
FIG. 1. Multislice RARE images
of the mouse brain (C57BL/6) with
the volumes of interest (VOIs)
centered in cerebral cortex, hip-
pocampus, striatum, and cerebel-
lum and in vivo 1H NMR spectra
measured from the correspond-
ing brain regions. RARE MRI: in-
plane resolution 80  80 m,
slice thickness 1 mm, TE 
60 ms, TR  4 sec. Localization
sequence: STEAM, TE  2 ms,
TR  5 sec, NT  160–320,
VOI  5–10 L. Processing:
Gaussian multiplication {f(t) 
exp(-(t–tmax)
2/22), tmax  0.05 s,
  0.085 s}, FT, zero-order
phase correction. No water signal
removal or baseline corrections
were applied.
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neurochemical proﬁles of different mouse strains were
very similar (Fig. 4). The differences in metabolite concen-
trations between strains did not exceed 13% and only the
differences in Gln, Glu, Ins, Lac, NAAG, and PE reached
the level of signiﬁcance (P  0.05, ANOVA).
DISCUSSION
In vivo 1H NMR spectroscopy can beneﬁt from high mag-
netic ﬁelds, provided that macroscopic ﬁeld inhomogene-
ities, mostly caused by susceptibility differences between
tissues and surrounding air, are minimized. The achieved
spectral quality in mouse brain (Fig. 1) resulted from suc-
cessful shimming up to second-order, which required an
efﬁcient B0 mapping method and a shim system (shim
coils and shim drivers) strong enough to compensate the
ﬁeld distortions in the VOI. In the present study, all ﬁrst-
and second-order shims were automatically adjusted using
FASTMAP. In addition, a custom-designed second-order
shim coil set was adequate to generate the required shim
ﬁeld strengths in most of the experiments. Demands for the
second-order shim strength in the hippocampus of mice
were up to 4 times higher than in the hippocampus of rats
(Fig. 2a). On average, the shim strengths required for dif-
ferent mouse brain locations were below 0.03 mT/cm2 for
the XZ, YZ, and Z2 coils and below 0.005 mT/cm2 for XY
and X2Y2 coils (Fig. 2b). Taking into account the fact that
in some brain regions the required shim strengths ex-
ceeded the available maximum, the maximal strengths of
all second-order shim coils should be approximately twice
as high as the average shim strengths assessed experimen-
tally (Fig. 2). Therefore, the desired shim coil should be at
least 0.06 mT/cm2 for XZ, YZ, Z2 and at least 0.01 mT/cm2
for XY and X2Y2 for spectroscopy of mouse brain at 9.4 T.
The effects of an unwanted B0 ﬁeld drift of the shim coil
was minimized by incrementing all frequencies in the
pulse sequence from scan to scan to follow the ﬁeld drift
and any residual frequency drift between spectra was
eliminated by postprocessing. However, such an approach
is not easily implemented for long-term averaging or CSI
experiments and thus strong second-order shim coils with-
out any ﬁeld drift would be desirable.
In addition to shimming, pulse sequence performance
was also important to achieve the spectral quality of this
study (Fig. 1). As in our previous studies, focused on rat
brain (20–23,28), the combination of STEAM with OVS
guaranteed high localization performance with minimal
contamination by signals from outside the VOI, such as
signals from subcutaneous lipids. VAPOR water suppres-
sion was used to eliminate potential baseline distortions
due to the residual water signal and permitted the reliable
detection of metabolite signals in the entire chemical shift
range (except for the 4.3–5.1 ppm range suppressed by
VAPOR). The achieved spectral quality allowed fully au-
tomatic and operator independent data processing, which
included the LCModel ﬁtting.
The sensitivity at 9.4 T provided S/N  10 from VOIs as
small as 5–10 L in a reasonable measuring time (15–
25 min) resulting in CRLB below 20% for most of the
metabolites. A high spatial resolution was required due to
the small sizes of the mouse brain regions investigated
(Fig. 1) and signiﬁcant differences in their neurochemical
proﬁle (Fig.3c). While larger VOIs would result in better
S/N, the regional speciﬁcity of the detected NMR signals
would obviously be lost. In addition, larger VOIs result in
reduced spectral resolution due to uncompensated third-
and higher-order shim terms, which can complicate the
reliable quantiﬁcation of metabolites. Sensitivity can be
further increased by using spin-echo based single-shot lo-
calization methods such as PRESS (29) or LASER (30), but
this can typically be achieved only at the expense of in-
creased echo time, which may result in more complicated
spectral pattern and additional signal loss due to J-evolu-
tion and T2 relaxation.
A high spectral quality (i.e., a high spectral resolution,
sufﬁcient S/N, excellent localization performance, efﬁ-
cient water suppression, and a distortionless baseline) was
important to achieve reliable quantiﬁcation of metabolite
concentrations. The reliability of metabolite quantiﬁcation
was assessed from the average Cramer-Rao lower bounds
computed by LCModel. CRLB are widely used in signal
FIG. 2. Requirements for the second-order shim strengths to com-
pensate the ﬁeld inhomogeneities in the rodent brain at 9.4 T. a:
Average shim requirements for hippocampus of adult rats (n  25),
newborn rats (n  18), and adult mice (n  15). Shaded areas
represent available shim strength. b: Average shim requirements for
different brain regions of C57BL/6 mice; cerebral cortex (n  7),
hippocampus (n  8), striatum (n  6), cerebellum (n  6). Shaded
areas represent the available shim strength. Labels on the top of
bars represent the ratio of the number of cases when the requested
shim values exceeded the maximum shim strength relative to the
total number of studied animals.
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processing as a measure of attainable precision for the
parameter estimates from a given set of observations (31).
Coefﬁcients of variation resulting from the analysis of a
series of experiments were not considered as a reliable
indicator for the accuracy of the metabolite quantiﬁcation
(32,33). CRLB, a highly important component of the stan-
dard output of the LCModel analysis (26,27), were be-
tween 3% and 20% for all mouse brain regions and for
most of the metabolites (Fig. 3a). Only weakly represented
metabolites of low concentration, such as Ala, Asp,
NAAG, and PE, were ﬁtted with CRLB exceeding 20%. In
contrast to the CRLB (expressed in %), the CRLB expressed
in concentration units (mol/g) indicated that the absolute
error was nearly independent of the metabolite concentra-
tion (Fig. 3b). This implies that the S/N ratio was the most
signiﬁcant factor in determining the precision of the me-
tabolite quantiﬁcation. This estimated error of metabolite
quantiﬁcation in the mouse brain was higher than the error
(0.2 mol/g) reported in the developing rat brain at 9.4 T
(22). This difference in precision was attributed to the
lower S/N of spectra in the mouse brain relative to the rat
brain (22,23) due to the smaller VOIs selected.
The comparison of metabolite concentrations in the ce-
rebral cortex, hippocampus, striatum, and cerebellum re-
vealed substantial and highly signiﬁcant regional varia-
tions (Fig. 3c). Regional differences in the neurochemical
proﬁle were also discernible from a careful inspection of
the spectra (Fig. 1). A substantially increased number of
reliably quantiﬁed metabolites in the mouse brain in vivo
relative to previously published data (7–15) allowed the
characterization of a neurochemical proﬁle speciﬁc and
unique for each brain region (cerebral cortex, hippocam-
pus, striatum, and cerebellum).
The brain concentration of total creatine in this study,
calculated as a mean of total Cr concentration from hip-
pocampus, striatum, and cerebral cortex, was 8.9 mol/g.
FIG. 3. Concentrations of brain
metabolites and corresponding
Cramer-Rao lower bound quanti-
ﬁed by LCModel in the cerebral
cortex (n  7), hippocampus (n 
8), striatum (n  6), and cerebel-
lum (n  6) of C57BL/6 mice. a:
CRLB expressed in relative units
(%). b: CRLB expressed in con-
centration units (mol/g). c: Me-
tabolite concentrations, error
bars  SD. Signiﬁcance level
(ANOVA): *P  0.05, **P  0.005,
***P  0.0001, ****P  0.00001.
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This value was in excellent agreement with the published
values of 9.2	 1.6 mmol/L (14) and 8.2	 1.2 mmol/L (15).
However, there are substantial differences in absolute con-
centrations of other metabolites such as Cho, Gln, Glu, Ins,
NAA, and Tau. The differences in measured metabolite
concentrations may be explained by the different spectral
quality of the compared datasets, speciﬁcally the spectral
resolution, as well as the differences in data processing
used. The spectral quality achieved in this study, espe-
cially the high spectral resolution and S/N in spite of the
very small VOIs, guaranteed low CRLB and thus reliable
quantiﬁcation. The CRLB of quantiﬁed metabolites (a good
estimate of the reliability of the data) were not reported in
the aforementioned articles (14,15). In addition, the choice
of metabolites included in the basis set of LCModel and
especially the incorporation of a spectrum of macromole-
cules for short TE spectra can also minimize systematic
errors in quantiﬁcation (34). For example, the unphysi-
ologically high concentrations of Glc reported in Ref. 14
can be explained by a substantial contribution from Tau
(not reported in Ref. 14), which has signiﬁcant spectral
overlap with glucose at 2.35 T. Comparison of the in vivo
with the in vitro data from the brain extracts is difﬁcult
due to the substantial variation in reported values (12,35–
37). Nevertheless, our metabolite concentrations (Fig. 3c)
were in very good agreement (except NAA) with brain
extract data reported by Jenkins et al. (12). In addition, the
difference in neurochemical proﬁle between cerebral cor-
tex and striatum, e.g., higher concentrations of NAA and
Tau or lower concentrations of GABA and Gln in the
cortex relative to striatum, were in agreement with this
earlier study (12).
Interstrain differences in metabolite concentrations
were small (13%) and limited to Gln, Glu, Ins, Lac,
NAAG, and PE. A previous study has reported substan-
tially larger differences in metabolite concentrations be-
tween other mouse strains (14). Several factors may ac-
count for these differences. For example, we noted that the
shimming resulted in 3-fold broader line widths (in ppm)
at 2.35 T (14) relative to our data and, in addition, line
widths decreased rather than increased postmortem,
which points to some difﬁculties with shimming. We fur-
ther noted too high in vivo concentration of Glc, nonzero
postmortem concentration of Glc, missing information
about Tau (the metabolite with the highest concentration
in the mouse brain according to our data), all pointing to
systematic errors in quantiﬁcation (14). In addition, the
selection of large VOIs could also bias interstrain compar-
ison, if regional metabolite variation and interstrain differ-
ences in the brain anatomy were not taken into account
(38).
A close similarity in the neurochemical proﬁles of hip-
pocampus, striatum, and cerebral cortex was found be-
tween mice and rats (22). For example, in the mouse brain
as well as in the rat brain, Ala was always highest in
striatum, Glu was highest in cortex, GSH was lowest in
cortex, NAA was lowest in striatum, Ins was highest in
hippocampus, Lac, Tau, and GPC  PCho were highest in
striatum. These observations suggest that the pattern of the
neurochemical proﬁle may express the speciﬁcs of a given
brain region across different species even though the ab-
solute metabolite concentrations between species are dis-
tinctly different. For example, the NAA concentration was
only 8 mol/g in the cortex of mice, whereas it was
10 mol/g in the cortex of rats, or the taurine concentra-
tion in the cortex was as high as 11 mol/g in mice and
only 8 mol/g in rats (22). Similar to the observations in
rat and mouse brain, high concentration of creatine in the
cerebellum (39) and of myo-inositol in the hippocampus
(40) relative to other brain regions were reported in hu-
mans. These observations raise the interesting possibility
that the neurochemical proﬁle reﬂects regional differences
in function and/or neuroanatomy, in addition to the rela-
tive gray and white matter content.
We conclude that at high ﬁeld, with appropriate adjust-
ments in spectrometer hardware and experimental tech-
niques, in vivo 1H NMR spectroscopy can provide highly
speciﬁc and precise biochemical information (neurochem-
ical proﬁle) characteristic for particular regions of the
mouse brain. These experimental capabilities may allow
longitudinal studies for monitoring of disease progression
and treatment as well as noninvasive phenotyping in
transgenic mice models.
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